Organization | University of Bratislava

University of Bratislava Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2007

NCT01423500

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Alternative names

CU in Bratislava, Faculty of Medicine, Pharmacobiochemical Laboratory of 3rd department of Medicine | HSCT Unit, University Children's Hospital Bratislava | University Hospital in Bratislava

Active Ingredients

Drugs in Phase 3 Trials (6)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

etoposide (vepesid) (1 trial)

fludarabine (fludara) (1 trial)

muromonab cd3 (Orthoclone OKT3) (1 trial)

thiotepa (1 trial)

treosulfan (1 trial)

Drugs in Other Trials (1)

l-carnosine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 7